Get the Stockscreener App
4.38
28.90%
-1.78
Galectin Therapeutics Inc stock is traded at $4.38, with a volume of 4.10M.
It is down -28.90% in the last 24 hours and down -23.69% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$6.16
Open:
$4.64
24h Volume:
4.10M
Relative Volume:
9.27
Market Cap:
$282.39M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-6.00
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
-29.92%
1M Performance:
-23.69%
6M Performance:
+33.13%
1Y Performance:
+119.00%
1-Day Range:
$3.80
$4.83
1-Week Range:
$3.80
$7.13
52-Week Range:
$0.726
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.38 | 397.15M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics (GALT) Price Target Increased by 83.33% to 11.22 - Nasdaq
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) Insider Sells 19,442 Shares of Stock - MarketBeat
Joel Lewis Sells 7,829 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Director Harold Shlevin Sells 24,499 Shares - MarketBeat
FDA provides feedback on Galectin’s belapectin development program By Investing.com - Investing.com Nigeria
Galectin Therapeutics (GALT) Shares Drop After FDA Update and Ne - GuruFocus
Why Galectin Therapeutics Inc. stock is favored by pension funds2025 Big Picture & Proven Capital Preservation Methods - ulpravda.ru
Galectin falls on MASH candidate belapectin update, additional $10M credit line - Seeking Alpha
Galectin Shares Fall After FDA Raises Issues With Belapectin Program - marketscreener.com
Why Did GALT Shares Plummet Over 30% Today? - Asianet Newsable
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line - marketscreener.com
Galectin Therapeutics stock plummets after FDA feedback on drug - Investing.com
Galectin Therapeutics stock plummets after FDA feedback on drug By Investing.com - Investing.com UK
Galectin Therapeutics enters line of credit agreement - marketscreener.com
Galectin Therapeutics (GALT) Aligns with FDA on Belapectin Trial - GuruFocus
Galectin Therapeutics provides regulatory update following FDA written response - marketscreener.com
FDA provides feedback on Galectin’s belapectin development program - Investing.com India
Galectin Advances Belapectin Program, Secures New Insider Financing - TipRanks
Galectin Therapeutics Receives FDA Feedback on Belapectin Development Program and Secures $10 Million Financing - Quiver Quantitative
Galectin Therapeutics Signs Supplemental Line of Credit Agreement With Richard E. Uihlein - TradingView — Track All Markets
New funding keeps potential liver cirrhosis treatment on track to 2027 - Stock Titan
Will Galectin Therapeutics Inc. stock benefit from automation2025 Market WrapUp & Accurate Entry/Exit Alerts - DonanımHaber
What dividend safety score for Galectin Therapeutics Inc. stockJuly 2025 Snapshot & Advanced Swing Trade Entry Alerts - DonanımHaber
Will Galectin Therapeutics Inc. stock see insider buyingPortfolio Update Summary & Weekly Breakout Stock Alerts - DonanımHaber
Should I hold or sell Galectin Therapeutics Inc. stock in 20252025 Top Decliners & Verified Momentum Stock Ideas - ulpravda.ru
Bull Bear: Should I hold or sell Galectin Therapeutics Inc. stock in 2025Weekly Profit Summary & Technical Pattern Based Buy Signals - ulpravda.ru
Fund L.P. 10X Sells 30,681 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
What analysts say about Galectin Therapeutics Inc stockRisk Adjusted Returns & Free High Return Strategy Alerts - earlytimes.in
Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened - Defense World
Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
HC Wainwright & Co. Maintains Galectin Therapeutics (GALT) Buy Recommendation - Nasdaq
GALT: HC Wainwright & Co. Raises Price Target to $11, Maintains Buy Rating | GALT Stock News - GuruFocus
Fundamentals Check: Will Galectin Therapeutics Inc stock benefit from AI adoptionDay Trade & Real-Time Market Sentiment Alerts - moha.gov.vn
Market Pulse: Will Galectin Therapeutics Inc stock benefit from AI adoptionJuly 2025 Sentiment & Daily Stock Trend Watchlist - moha.gov.vn
Galectin therapeutics director sells shares worth $1.05 million By Investing.com - Investing.com Canada
Galectin Therapeutics (NASDAQ:GALT) Director Sells $105,273.30 in Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Director Sells $950,820.00 in Stock - MarketBeat
Galectin therapeutics director sells shares worth $1.05 million - Investing.com India
Galectin Therapeutics Insider Sold Shares Worth $1,055,311, According to a Recent SEC Filing - marketscreener.com
Dir Shlevin Sells 175,790 ($1.1M) Of Galectin Therapeutics Inc [GALT] - TradingView — Track All Markets
There is no way Galectin Therapeutics Inc (GALT) can keep these numbers up - Setenews
Galectin Therapeutics shareholders elect board members and approve key proposals By Investing.com - Investing.com Nigeria
10x fund sells Galectin Therapeutics (GALT) shares worth $920,855 By Investing.com - Investing.com Australia
10x fund sells Galectin Therapeutics (GALT) shares worth $920,855 - Investing.com
Galectin Therapeutics : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Galectin Therapeutics shareholders elect board members and approve key proposals - Investing.com
Galectin Therapeutics (NASDAQ:GALT) Major Shareholder Fund L.P. 10X Sells 30,000 Shares - MarketBeat
Prepare Yourself for Liftoff: Galectin Therapeutics Inc (GALT) - Setenews
How Galectin Therapeutics Inc. (PHPN) stock reacts to Fed tighteningJuly 2025 Volume & Daily Growth Stock Tips - Newser
Is Galectin Therapeutics Inc. (PHPN) stock a contrarian opportunityBear Alert & Safe Capital Growth Stock Tips - Newser
10x fund sells Galectin therapeutics (GALT) shares worth $851,700 - Investing.com India
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):